SEARCH

SEARCH BY CITATION

References

  • 1
    Zuberbier T, Greaves MW, Juhlin L, Merk H, Stingl G, Henz BM. Management of urticaria – a consensus report. J Invest Dermatol Symp Proc 2001;6: 128131.
  • 2
    Wüthrich B. Adverse reactions to food additives. Ann Allergy 1993;71: 379384.
  • 3
    Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004;4: 387396.
  • 4
    Wedi B, Kapp A. Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol 2002;3: 273282.
  • 5
    Henz BM, Zuberbier T. Causes of urticaria. In: HenzBM, ZuberbierT, GrabbeJ, MonroeE, editors. Urticaria. Clinical, diagnostic and therapeutic aspects. Berlin: Springer, 1998: 1938.
  • 6
    Champion RH, Roberts SOB, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969;81: 588597.
  • 7
    Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria. Acta Derm Venereol (Stockh) 1995;75: 484487.
  • 8
    Bruno G, Andreozzi P, Graf U. Exercise-induced urticaria – angioedema syndrome: a role in gastroesophageal reflux. In: VenaGA, PudduP, editors. Proceedings of the International Symposium on Urticaria. Bari: Publ Scientif., 1998: 8589.
  • 9
    Grattan CEH, Francis DM, Slater NGP, Barlow RJ, Greaves MW. Plasmapheresis for severe unremitting chronic urticaria. Lancet 1992;339: 10781080.
  • 10
    Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000;105: 664672.
  • 11
    Grattan CEH, O'donnell BFO, Francis DM, Niimi N, Barlow RJ, Seed PT et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000;143: 365372.
  • 12
    Barlow RJ, Black AK, Greaves MW. Treatment of severe chronic urticaria with cyclosporin A. Eur J Dermatol 1993;3: 273275.
  • 13
    Fradin MS, Ellis CN, Goldfarb MT, Voorhees JJ. Oral cyclosporin for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991;25: 10651067.
  • 14
    Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997;52: 312316.
  • 15
    O'donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998;138: 101106.
  • 16
    Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981;104: 369381.
  • 17
    Pfrommer C, Bastl R, Vieths S, Ehlers I, Henz BM, Zuberbier T. Characterization of naturally occurring pseudoallergens causing chronic urticaria. J Allergy Clin Immunol 1996;97: 367.
  • 18
    Pigatto PD, Valsecchi RH. Chronic urticaria: a mystery. Allergy 2000;55: 306308.
  • 19
    Zuberbier T, Iffländer J, Semmler C, Czarnetzki BM. Acute urticaria – clinical aspects and therapeutical responsiveness. Acta Derm Venereol (Stockh) 1996;76: 295297.
  • 20
    Stellato C, De Paulis A, Ciccarelli A, Cirillo R, Patella V, Casolaro V et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98: 800804.
  • 21
    Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195: 3539.
  • 22
    Horio T. Indications and action mechanisms of phototherapy. J Dermatol Sci 2000;23(Suppl. 1):S17S21.
  • 23
    Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol 1985;65: 449450.
  • 24
    Olafsson JH, Larko O, Roupe G, Granerus G, Bengtsson U. Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study. Acta Dermatol Res 1986;278: 228231.
  • 25
    Beissert S, Stander H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol 2000;42: 10301032.
  • 26
    Lippert U, Krüger-Krasagakes S, Möller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist descarboethoxy-loratadine and dexamethasone from human mast and basophilic cell lines. Exp Dermatol 1995;4: 272276.
  • 27
    Lippert U, Möller A, Welker P, Artuc M, Grützkau A, Henz BM. Inhibition of cytokine secretion from human mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9: 118124.
  • 28
    Merk H, Sauer RR, Steigleder GK. Histamine release in cold urticaria – effect of ketotifen and oxatomide. In: ChampionRH, GreavesMW, Kobza-BlackA, PyeRJ, editors. The urticarias. London: Churchill Livingston, 1985: 222223.
  • 29
    Zuberbier T, Münzberger CH, Haustein U, Trippas E, Mariz SD, Czarnetzki BM. Double-blind crossover study of high dose cetirizine in cholinergic urticaria. Dermatology 1996;193: 324327.
  • 30
    Kontou-Fili K, Maniakatou G, Demaka P, Paleologos G. Therapeutic effect of cetirizine 2HCl in delayed pressure urticaria. Health Sci Rev 1989;3: 2325.
  • 31
    Lindquist M, Edwards R. Risks of non-sedating antihistamines. Lancet 1997;349: 1322.
  • 32
    Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin Immunol 1997;99: 860861.
  • 33
    Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999;29(Suppl. 3):116124.
  • 34
    Thormann J, Laurberg G, Zachariae H. Oral sodium cromoglycate in chronic urticaria. Allergy 1980;35: 139141.
  • 35
    Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977;57: 369370.
  • 36
    Lawlor F, Ormerod AD, Greaves MW. Calcium antagonist in the treatment of symptomatic dermographism. Low-dose and high-dose studies with nifedipine. Dermatologica 1988;177: 287291.
  • 37
    Lawlor F, Black AK, Ward AM, Morris R, Greaves MW. Delayed pressure urticaria, objective evaluation of variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989;120: 403408.
  • 38
    Dover JS, Kobza-Black A, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 1988;18: 12891298.
  • 39
    O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136: 197201.
  • 40
    Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58: 621623.
  • 41
    Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability on different urticarial conditions. Br J Dermatol 1999;140: 667671.
  • 42
    Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerru L, Compalati E et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005;60: 10731078.
  • 43
    Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol 1996;76: 295297.
  • 44
    Simons FER. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunol 2001;107: 703706.
  • 45
    Pollack CV, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med 1995;26: 547551.
  • 46
    Watson NT, Weiss EL, Harter PM. Famotidine in the treatment of acute urticaria. Clin Exp Dermatol 2000;25: 186189.
  • 47
    Pontasch MJ, White LJ, Bradford JC. Oral agents in the management of urticaria: patient perception of effectiveness and level of satisfaction with treatment. Ann Pharmacother 1993;27: 730731.
  • 48
    Moscati RM, Moore GP. Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria. Ann Emerg Med 1990;19: 1215.
  • 49
    Camarasa JM, Aliaga A, Fernandez-Vozmediano JM, Fonseca E, Iglesias L, Tagarro I. Azelastine tablets in the treatment of chronic idiopathic urticaria. Phase III, randomised, double-blind, placebo and active controlled multicentric clinical trial. Skin Pharmacol Appl Skin Physiol 2001;14: 7786.
  • 50
    Henz BM, Metzenauer P, O'keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy 1998;53: 180183.
  • 51
    La Rosa M, Leonardi S, Marchese G, Corrias A, Barberio G, Oggiano N et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001;87: 4853.
  • 52
    Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004;15: 5557.
  • 53
    Lambert D, Hantzperg M, Danglas P, Bloom M. Double-blind comparative study of terfenadine and cetirizine in chronic idiopathic urticaria. Allergy Immunol (Paris) 1993;25: 235240.
  • 54
    Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996;30: 10751079.
  • 55
    Breneman D, Bronsky EA, Bruce S, Kalivas JT, Klein GL, Roth HL et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol 1995;33: 192198.
  • 56
    Andri L, Senna GE, Betteli C, Givanni S, Andri G, Lombardi C et al. A comparison of the efficacy of cetirizine and terfenadine. A double-blind, controlled study of chronic idiopathic urticaria. Allergy 1993;48: 358365.
  • 57
    Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria—a double blind randomised cross-over study. Ann Acad Med Singapore 1991;20: 328330.
  • 58
    Juhlin L. Cetirizine in the treatment of chronic urticaria. Clin Ther 1991;13: 8186.
  • 59
    Alomar A, De La C, Fernandez J. Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria. J Int Med Res 1990;18: 358365.
  • 60
    Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990;86: 10141018.
  • 61
    Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol 1988;119: 6771.
  • 62
    Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003;48: 535541.
  • 63
    Monroe EW. Desloratidine for the treatment of chronic urticaria. Skin Therapy Lett 2002;7: 12, 5.
  • 64
    Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40: 7276.
  • 65
    Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996;52(Suppl. 1):3034.
  • 66
    Peyri J, Vidal J, Marrón J, Fonseca E, Suãrez E, Ledo A et al. Ebastine in chronic urticaria: a double-blind placebo-controlled study. J Dermatolog Treat 1991;2: 5153.
  • 67
    Degonda M, Pichler WJ, Bircher A, Helbling A. Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients. Schweiz Rundsch Med Prax 2002;91: 637643.
  • 68
    Kawashima M, Harada S, Tango T. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol 2002;41: 701706.
  • 69
    Kawashima M, Harada S. Efficacy and safety of fexofenadine HCl in Japanese patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2001;124: 343345.
  • 70
    Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84: 517522.
  • 71
    Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43: 2430.
  • 72
    Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind placebo-controlled, parallel, multicenter study. Int J Dermatol 2005; DOI: 10.1111/j.1365-4632.2005.02609.
  • 73
    Kapp A, Wedi B. Chronic urticaria: clinical aspects, and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004;3: 632639.
  • 74
    Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992;14: 1721.
  • 75
    Belaich S, Bruttmann G, Degreef H, Lachapelle JM, Paul E, Pedrali P et al. Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy 1990;64: 191194.
  • 76
    Monroe EW, Fox RW, Green AW, Izuno GT, Bernstein DI, Pleskow WW et al. Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria. J Am Acad Dermatol 1988;19: 138139.
  • 77
    Kapp A, Guinnepain MT, Lachapelle JM, Murrieta-Aguttes M. Mizolastine in the treatment of chronic urticaria: a European clinical experience with 2452 patients managed in daily practice (PANEOS CU Study). In: MaroneG, editor. Clinical immunology and allergy in medicine. Naples: JGC Editions, 2003.
  • 78
    Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur J Dermatol 2000;10: 205211.
  • 79
    Lorette G, Giannetti A, Pereira RS, Leynadier F, Murrieta-Aguttes M. One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group. J Eur Acad Dermatol Venereol 2000;14: 8390.
  • 80
    Dubertret L, Murrieta AM, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol 1999;12: 1624.
  • 81
    Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. Clin Exp Allergy 1999;29(Suppl. 1):3137.
  • 82
    Lachapelle JM, Tennstedt D, Murrieta M. Comparative efficacy and safety of mizolastine 10 mg o.d. versus placebo in chronic idiopathic urticaria. Allergy 1998;53: 57.
  • 83
    Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996;51: 320325.
  • 84
    Grattan CE, O'Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000;143: 365372.
  • 85
    Di Lorenzo G, Pacor ML, Mansueto P, Pellitteri ME, Lo Bianco C, Ditta V et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004;114: 619625.
  • 86
    Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004;34: 14011407.
  • 87
    Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110: 484488.
  • 88
    Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987;117: 8188.
  • 89
    Diller G, Orfanos CE. Management of idiopathic urticaria with H1 + H2 antagonists. A crossover double blind long-term study. Z Hautkr 1983;58: 785793.
  • 90
    Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981;68: 262266.
  • 91
    Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981;117: 404407.
  • 92
    Goldsobel AB, Rohr AS, Siegel SC, Spector SL, Katz RM, Rachelefsky GS et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986;78: 867873.
  • 93
    Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985;12: 669675.
  • 94
    Harto A, Sendagorta E, Ledo A. Doxepin in the treatment of chronic urticaria. Dermatologica 1985;170: 9093.
  • 95
    Kamide R, Niimura M, Ueda H, Imamura S, Yamamoto S, Yoshida H et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. Ann Allergy 1989;62: 322325.
  • 96
    Reeves GEM, Boyle MJ, Bonfield J, Dobson P. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Int Med J 2004;34: 182186.
  • 97
    Baumgart KW, Mullins R. Use of hydroxychloroquine in refractory urticaria. J Allergy Clin Immunol 2000;105: 795796.
  • 98
    Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001;28: 299302.
  • 99
    Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004;113: 134140.
  • 100
    Beck HI, Cramers M, Herlin T, Sondergaard I, Zachariae H. Comparison of oxatomide and clemastine in the treatment of chronic urticaria. A double blind study. Dermatologica 1985;171: 4951.
  • 101
    Demaubeuge J, Tennstedt D, Broux R. Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. Dermatologica 1982;164: 386394.
  • 102
    Peremans W, Mertens RL, Morias J, Campaert H. Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. Dermatologica 1981;162: 4250.
  • 103
    Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol 1989;83: 756763.
  • 104
    Nettis E, Dambra P, D'oronzio L, Loria MP, Ferrannini A, Tursi A. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001;137: 99100.
  • 105
    Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001;31: 16071614.
  • 106
    Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000;30: 11611165.
  • 107
    Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angio-edema. Br J Dermatol 1992;126: 415416.
  • 108
    Sharpe GR, Shuster S. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol 1993;129: 580583.
  • 109
    Cap JP, Schwanitz HJ, Czarnetzki BM. Effect of ketotifen in urticaria factitia and urticaria cholinergica in a crossover double-blind trial. Hautarzt 1985;36: 509511.
  • 110
    Kontou-Fili K, Maniatakou G, Demaka P, Gonianakis M, Palaiogolos G, Aroni K. Therapeutic effects of cetirizine 2HCl in delayed pressure urticaria: clinicopathologic findings. J Am Acad Dermatol 1991;24: 10901093.
  • 111
    Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 2003;112: 212213.
  • 112
    Vena GA, D'argento V, Cassano N, Mastrolonardo M. Sequential therapy with nimesulide and ketotifen in delayed pressure urticaria. Acta Derm Venereol (Stockh) 1998;78: 304305.
  • 113
    Barlow RJ, Macdonald DM, Black AK, Greaves MW. The effects of topical corticosteroids on delayed pressure urticaria. Arch Dermatol Res 1995;287: 285288.
  • 114
    Juhlin L. Inhibition of cold urticaria by desloratadine. J Dermatolog Treat 2004;15: 5159.
  • 115
    Bonadonna P, Lombardi C, Senna G, Canonica GW, Passalacqua G. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol 2003;49: 714716.
  • 116
    Dubertret L, Pecquet C, Murrieta-Aguttes M, Leynadier F. Mizolastine in primary acquired cold urticaria. J Am Acad Dermatol 2003;48: 578583.
  • 117
    Villas MF, Contreras FJ, Lopez Cazana JM, Lopez Serrano MC, Martinez AF. A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU). J Investig Allergol Clin Immunol 1992;2: 258262.
  • 118
    Wanderer AA, St Pierre PJ, Ellis EF. Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol 1977;113: 12751277.
  • 119
    St Pierre JP, Kobric M, Rackham A. Effect of ketotifen treatment on cold-induced urticaria. Ann Allergy 1985;55: 840843.
  • 120
    Roelandts R. Diagnosis and treatment of solar urticaria. Dermatol Ther 2003;16: 5256.
  • 121
    Bilsland D, Ferguson J. A comparison of cetirizine and terfenadine in the management of solar urticaria. Photodermatol Photoimmunol Photomed 1991;8: 6264.
  • 122
    Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol 1995;75: 147149.
  • 123
    Zuberbier T, Munzberger C, Haustein U, Trippas E, Burtin B, Mariz SD et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996;193: 324327.
  • 124
    Wong E, Eftekhari N, Greaves MW, Ward AM. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol 1987;116: 553556.
  • 125
    Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981;68: 262266.
  • 126
    Spangler DL, Vanderpool GE, Carroll MS, Tinkelman DG. Terbutaline in the treatment of chronic urticaria. Ann Allergy 1980;45: 246247.
  • 127
    Reimers A, Pichler C, Helbling A, Pichler WJ, Yawalkar N. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002;32: 17631768.
  • 128
    Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977;57: 369370.
  • 129
    Thormann J, Laurberg G, Zachariae H. Oral sodium cromoglycate in chronic urticaria. Allergy 1980;35: 139141.
  • 130
    Lawlor F, Black AK, Ward AM, Morris R, Greaves MW. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989;120: 403408.
  • 131
    Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 1988;18: 12891298.
  • 132
    Sharpe GR, Shuster S. In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone. Br J Dermatol 1993;129: 575579.
  • 133
    Matthews CN, Boss JM, Warin RP, Storari F. The effect of H1 and H2 histamine antagonists on symptomatic dermographism. Br J Dermatol 1979;101: 5761.
  • 134
    Lawlor F, Ormerod AD, Greaves MW. Calcium antagonist in the treatment of symptomatic dermographism. Low-dose and high- dose studies with nifedipine. Dermatologica 1988;177: 287291.